Vitamin D3 aids obesity managementUnveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients.
Most Relevant Research
We set out to investigate how vitamin D3 affects obesity, particularly in obese patients facing obstructive sleep apnea (OSA). Our study included patients who were randomly assigned to receive either dapagliflozin (an SGLT2 inhibitor), vitamin D3, both treatments together, or no treatment at all over a period of 16 weeks.
The focus was on various health parameters such as body measurements, blood sugar levels, cholesterol, liver conditions, and quality of life. We discovered that combining vitamin D3 with SGLT2 inhibitors showed promising results. This combination seemed to improve not just physical health markers but also the overall quality of life in hypertensive, obese individuals with OSA.
By revealing these positive effects, we highlight how vitamin D3 can contribute to better management of obesity-related complications, particularly when paired with SGLT2 inhibitors. Our findings suggest a potential strategy to address the intertwined challenges of obesity, metabolic health, and sleep disturbances in this patient population.